THE PROFILE AND CLINICAL EVIDENCE OF EFFECTIVENESS OF OLAPARIB IN TRIPLENEGATIVE BREAST CANCER: A REVIEW
DOI:
https://doi.org/10.46799/ijssr.v4i8.885Keywords:
profile, clinical evidence, Olaprib, triple negative breast cancerAbstract
Triple-negative breast cancer (TNBC) is one of the most common malignancies in women. The majority of patients with TNBC have a poor prognosis. The main objective of this study is to review the profile and clinical evidence of the effectiveness of Olaparib in treating TNBC. A literature search was conducted using multiple electronic databases, including PubMed, Google Scholar, JSTOR, and Scopus. The search was focused on articles published up to June 2024, ensuring the inclusion of the latest and relevant studies. The primary objective was to investigate the mechanism of action, toxicity profile, resistance mechanisms, and therapeutic effectiveness of olaparib in the treatment of TNBC, regardless of their prior chemotherapy treatment for metastatic breast cancer, prior platinum-based chemotherapy, or usage of cyclin-dependent kinase 4/6 inhibitors (Balmana et al., 2022). The results of this research suggest that the pharmacological efficacy and safety characteristics of this medication in TNBC patients are similar to those reported in the OlympiAD study. Furthermore, stratification of patients for this medication is possible due to the diagnostic techniques that can predict the presence of the BRCA mutation in order to optimize its efficacies. Additionally, developing and validating new biomarkers beyond BRCA mutations for patient stratification could optimize targeted therapy approaches.
References
Bajrami, I., Frankum, J. R., Konde, A., Miller, R. E., Rehman, F. L., Brough, R., Campbell, J., Sims, D., Rafiq, R., Hooper, S., Chen, L., Kozarewa, I., Assiotis, I., Fenwick, K., Natrajan, R., Lord, C. J., & Ashworth, A. (2014). Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. Cancer Research, 74(1). https://doi.org/10.1158/0008-5472.CAN-13-2541
Balmana, J., Fasching, P. A., Delaloge, S., Park, Y. H., Eisen, A., Bourgeois, H., Kemp, Z., Jankowski, T., Sohn, J., Aksoy, S., Timcheva, C. V., Park-Simon, T.-W., Anton Torres, A., John, E., Baria, K., Walker, G., & Gelmon, K. A. (2022). 174P Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: Phase IIIb LUCY final analysis. Annals of Oncology, 33. https://doi.org/10.1016/j.annonc.2022.03.193
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6). https://doi.org/10.3322/caac.21492
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005). Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature, 434(7035). https://doi.org/10.1038/nature03443
Giaquinto, A. N., Sung, H., Miller, K. D., Kramer, J. L., Newman, L. A., Minihan, A., Jemal, A., & Siegel, R. L. (2022). Breast Cancer Statistics, 2022. CA: A Cancer Journal for Clinicians, 72(6). https://doi.org/10.3322/caac.21754
Giudice, E., Gentile, M., Salutari, V., Ricci, C., Musacchio, L., Carbone, M. V., Ghizzoni, V., Camarda, F., Tronconi, F., Nero, C., Ciccarone, F., Scambia, G., & Lorusso, D. (2022). PARP Inhibitors Resistance: Mechanisms and Perspectives. Cancers, 14(6). https://doi.org/10.3390/cancers14061420
Gunderson, C. C., & Moore, K. N. (2015). BRACAnalysis CDx as a companion diagnostic tool for Lynparza. Expert Review of Molecular Diagnostics, 15(9). https://doi.org/10.1586/14737159.2015.1078238
Guo, X. X., Wu, H. L., Shi, H. Y., Su, L., & Zhang, X. (2018). The efficacy and safety of olaparib in the treatment of cancers: A meta-analysis of randomized controlled trials. Cancer Management and Research, 10. https://doi.org/10.2147/CMAR.S169558
Hess, L. M., Brnabic, A., Mason, O., Lee, P., & Barker, S. (2019). Relationship between progression-free survival and overall survival in randomized clinical trials of targeted and biologic agents in oncology. Journal of Cancer, 10(16). https://doi.org/10.7150/jca.32205
Howard, F. M., & Olopade, O. I. (2021). Epidemiology of Triple-Negative Breast Cancer: A Review. Cancer Journal (United States), 27(1). https://doi.org/10.1097/PPO.0000000000000500
Im, S. A., Xu, B., Li, W., Robson, M., Ouyang, Q., Yeh, D. C., Iwata, H., Park, Y. H., Sohn, J. H., Tseng, L. M., Goessl, C., Wu, W., & Masuda, N. (2020). Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Scientific Reports, 10(1). https://doi.org/10.1038/s41598-020-63033-4
Lau, C. H., Seow, K. M., & Chen, K. H. (2022). The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review. International Journal of Molecular Sciences, 23(15). https://doi.org/10.3390/ijms23158125
Liao, H., Ji, F., Helleday, T., & Ying, S. (2018). Mechanisms for stalled replication fork stabilization: new targets for synthetic lethality strategies in cancer treatments. EMBO Reports, 19(9). https://doi.org/10.15252/embr.201846263
Lin, K. K., Harrell, M. I., Oza, A. M., Oaknin, A., Ray-Coquard, I., Tinker, A. V., Helman, E., Radke, M. R., Say, C., Vo, L. T., Mann, E., Isaacson, J. D., Maloney, L., O’Malley, D. M., Chambers, S. K., Kaufmann, S. H., Scott, C. L., Konecny, G. E., Coleman, R. L., … Swisher, E. M. (2019). BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discovery, 9(2). https://doi.org/10.1158/2159-8290.CD-18-0715
Musolino, A., Bella, M. A., Bortesi, B., Michiara, M., Naldi, N., Zanelli, P., Capelletti, M., Pezzuolo, D., Camisa, R., Savi, M., Neri, T. M., & Ardizzoni, A. (2007). BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: A population-based study. Breast, 16(3). https://doi.org/10.1016/j.breast.2006.12.003
Peng, L., Xu, T., Long, T., & Zuo, H. (2016). Association between BRCA status and P53 status in breast cancer: A meta-analysis. Medical Science Monitor, 22. https://doi.org/10.12659/MSM.896260
Ricci, A. D., Rizzo, A., Novelli, M., Tavolari, S., Palloni, A., Tober, N., Abbati, F., Mollica, V., De Lorenzo, S., Turchetti, D., Di Marco, M., & Brandi, G. (2020). Specific toxicity of maintenance olaparib versus placebo in advanced malignancies: A systematic review and meta-analysis. Anticancer Research, 40(2). https://doi.org/10.21873/anticanres.13989
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., Wu, W., Goessl, C., Runswick, S., & Conte, P. (2017). Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation . New England Journal of Medicine, 377(6). https://doi.org/10.1056/nejmoa1706450
Rose, M., Burgess, J. T., O’Byrne, K., Richard, D. J., & Bolderson, E. (2020). PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance. Frontiers in Cell and Developmental Biology, 8. https://doi.org/10.3389/fcell.2020.564601
Rottenberg, S., Jaspers, J. E., Kersbergen, A., Van Der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., De Bruin, M., Zevenhoven, J., Lau, A., Boulter, R., Cranston, A., O’Connor, M. J., Martin, N. M. B., Borst, P., & Jonkers, J. (2008). High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proceedings of the National Academy of Sciences of the United States of America, 105(44). https://doi.org/10.1073/pnas.0806092105
Shu, Y., Ding, Y., He, X., Liu, Y., Wu, P., & Zhang, Q. (2023). Hematological toxicities in PARP inhibitors: A real-world study using FDA adverse event reporting system (FAERS) database. Cancer Medicine, 12(3). https://doi.org/10.1002/cam4.5062
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023). Cancer statistics, 2023. CA: A Cancer Journal for Clinicians, 73(1). https://doi.org/10.3322/caac.21763
Ström, C. E., Johansson, F., Uhlén, M., Szigyarto, C. A. K., Erixon, K., & Helleday, T. (2011). Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate. Nucleic Acids Research, 39(8). https://doi.org/10.1093/nar/gkq1241
Venkitaraman, A. R. (2014). Cancer suppression by the chromosome custodians, BRCA1 and BRCA2. Science, 343(6178). https://doi.org/10.1126/science.1252230
Wahba, H. A., & El-Hadaad, H. A. (2015). Current approaches in treatment of triple-negative breast cancer. Cancer Biology and Medicine, 12(2). https://doi.org/10.7497/j.issn.2095-3941.2015.0030
Zheng, F., Zhang, Y., Chen, S., Weng, X., Rao, Y., & Fang, H. (2020). Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer. Biomedicine and Pharmacotherapy, 123. https://doi.org/10.1016/j.biopha.2019.109661
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Muhammad Reza Al Faathiansyah
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-ShareAlike 4.0 International. that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
